TidalSense
TidalSense is a Cambridge-based medical device company that combines a patented CO2 breath sensor with AI algorithms trained on over 2.5 million breaths to deliver point-of-care COPD diagnosis and remote respiratory monitoring as a managed service to NHS Integrated Care Boards, pharmaceutical trial sponsors, and patients.
- Company typePrivate
- Founded2013
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What TidalSense does
TidalSense Ltd. is a Cambridge-based respiratory diagnostics company that has built the N-Tidal platform, comprising the CE-marked Class 2a N-Tidal Diagnose point-of-care COPD diagnostic and the N-Tidal Capture remote patient monitoring solution. The platform combines a patented CO2 breath sensor — developed over more than ten years — with a 4G-connected handheld device that automatically transmits breath data to a cloud backend, where machine learning algorithms trained on over 2.5 million breaths from clinical trials produce diagnostic and longitudinal monitoring outputs. The company targets NHS Integrated Care Boards, respiratory patients, and pharmaceutical companies conducting respiratory clinical trials, with NHS Suffolk and North East Essex ICB disclosed as its first commissioning customer in November 2025.
The business model is a fully managed diagnostic service delivered to NHS ICBs and healthcare providers, in which the device, sensor, connectivity, cloud, and AI analysis are bundled rather than sold as capital equipment. Pricing is negotiated at the ICB level and is not publicly disclosed, and revenue is not yet reported. Marketing reach is concentrated in earned media and LinkedIn-led digital channels, and the company is registered as a private limited company in England and Wales with funding to date from Business Growth Fund, Downing Ventures, Foresight Group, and a series of SBRI Healthcare grants.
Strategically, TidalSense is positioned at the start of its commercial scale-up phase: regulatory clearance under EU MDR has just been obtained, the first NHS commissioning has been announced, and an additional monitoring product (N-Tidal Capture) has been launched to extend the platform into longitudinal care. Competitive positioning rests on the patented sensor, the proprietary breath dataset, regulatory clearance, and a managed-service delivery model intended to reduce operational burden on healthcare providers while creating a recurring revenue stream as more ICBs adopt the diagnostic.
TidalSense firmographics
Firmographics- Name
- TidalSense
- Legal name
- TidalSense Ltd.
- Website
- https://tidalsense.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TidalSense is a Cambridge-based medical device company that combines a patented CO2 breath sensor with AI algorithms trained on over 2.5 million breaths to deliver point-of-care COPD diagnosis and remote respiratory monitoring as a managed service to NHS Integrated Care Boards, pharmaceutical trial sponsors, and patients.
- Ownership category
- akta.pro rank
Where TidalSense is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
TidalSense business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Managed Diagnostic Services: N-Tidal Diagnose is delivered as a fully managed service to healthcare providers, providing point-of-care COPD diagnostic testing. This model generates recurring revenue through service contracts with NHS ICBs and healthcare systems.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
TidalSense product offering
Product offeringCore offering
TidalSense develops and sells the N-Tidal respiratory intelligence platform, a CE-marked Class 2a medical device that combines a patented CO2 sensor and 4G-connected handheld device with a cloud-based AI platform to diagnose and monitor respiratory conditions. Its core commercial offerings are N-Tidal Diagnose (rapid point-of-care COPD diagnosis) and N-Tidal Capture (remote patient monitoring for longitudinal respiratory assessment), delivered as fully managed services to NHS Integrated Care Boards, healthcare providers, and pharmaceutical companies.
Product overview
TidalSense offers the N-Tidal® platform comprising two core products: N-Tidal® Diagnose (a CE-marked Class 2a medical device for point-of-care COPD diagnosis delivered as a fully managed service) and N-Tidal® Capture (a remote patient monitoring solution for longitudinal respiratory health assessment). Both products share a common patented CO2 sensor technology and connect via 4G to a cloud platform driven by AI algorithms that were trained on over 2.5 million breaths from clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- N-Tidal®: A powerful platform for diagnosing, monitoring and improving respiratory health through a best in class sensor, an easy-to-use device and regulated, secure, platform driven by exponentially powerful AI
- N-Tidal® Diagnose
- N-Tidal® Capture
Products and services
- N-Tidal® Diagnose CE-marked Class 2a medical device under EU MDR providing rapid, accurate, point-of-care COPD diagnostic testing delivered as a fully managed service to NHS Integrated Care Boards and healthcare providers.
- N-Tidal® Capture Remote patient monitoring solution powered by N-Tidal digital biomarkers, enabling longitudinal assessment of respiratory health for patients with COPD, asthma, and other respiratory conditions.
Quantifiable outcome
- Reduces COPD diagnosis waiting times
- +2 more outcomes
Companies that use TidalSense
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
TidalSense technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
TidalSense partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
TidalSense competitors and assessment
Company assessmentDirect peers
- NuvoAir: Digital respiratory health company offering remote spirometry and care management for COPD and asthma patients — directly overlapping with TidalSense's N-Tidal Diagnose and Capture products and target customer base (healthcare providers and payers).
- Propeller Health: Digital respiratory health platform (now part of ResMed) using sensors and software to monitor inhaler use in COPD/asthma — comparable in respiratory digital diagnostics, chronic disease management focus, and pharma-partnered business model.
- Vitalograph: UK-based manufacturer of spirometry and respiratory diagnostic devices used in clinical trials and primary care — directly competes with TidalSense on respiratory measurement hardware and on the clinical workflow for COPD diagnosis.
- MIR (Medical International Research): Global spirometry device manufacturer with connected/smart spirometers for primary care, occupational health, and clinical research — competes with N-Tidal on the underlying respiratory diagnostic device category.
- Cohero Health: Digital respiratory health company with connected inhaler sensors and spirometry — overlapping with TidalSense on COPD/asthma digital diagnostics and remote monitoring, serving similar healthcare-provider and pharma customers.
- HGE Health: COPD-focused digital health platform offering remote symptom monitoring and care coordination — a direct peer in COPD-specific respiratory digital care pathways and provider-facing solutions.
- Respiri: Respiratory health technology company developing wheeze detection and remote monitoring for asthma and COPD — closely comparable in remote respiratory diagnostics and consumer/provider facing hardware-plus-AI model.
Broad incumbents
- Clario: Large clinical trial technology services provider offering respiratory endpoints and eCOA across Phase II/III trials — directly relevant to TidalSense's pharma clinical-trial use case, though operating as a broad incumbent across many therapeutic areas.
- AstraZeneca: Global respiratory pharma with major COPD/asthma franchises (Symbicort, Breztri, Trixeo) and active digital respiratory initiatives — a relevant pharma customer/partner and a major force shaping COPD care pathways that TidalSense targets.
Emerging players
- Spire Health: Wearable respiratory monitoring company focused on continuous tracking of lung function and respiratory patterns — emerging overlap with TidalSense's remote patient monitoring roadmap and respiratory biomarker development.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TidalSense social profiles
Digital presenceTidalSense compliance and trust
Trust signalCompliance1 record
TidalSense financial estimates
Financial estimateRevenue estimate
Valuation estimate
TidalSense leadership team
Management profileNumber of profiles
Profiles1 record
TidalSense funding detail
Funding detailFunding overview
Funding rounds10 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TidalSense M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TidalSense
What does TidalSense do?
TidalSense develops and sells the N-Tidal respiratory intelligence platform, a CE-marked Class 2a medical device that combines a patented CO2 sensor and 4G-connected handheld device with a cloud-based AI platform to diagnose and monitor respiratory conditions. Its core commercial offerings are N-Tidal Diagnose (rapid point-of-care COPD diagnosis) and N-Tidal Capture (remote patient monitoring for longitudinal respiratory assessment), delivered as fully managed services to NHS Integrated Care Boards, healthcare providers, and pharmaceutical companies.
Is TidalSense a public or private company?
TidalSense is a private company. It is classified as venture growth investor backed and is currently operating.
When was TidalSense founded?
TidalSense was founded in 2013. It employs 11 to 50 people.
Where is TidalSense based?
TidalSense is headquartered in Cambridge, United Kingdom, in the Europe region.
How does TidalSense make money?
One revenue line is on record: managed Diagnostic Services.
Who are TidalSense's main competitors?
Direct peers on record are NuvoAir, Propeller Health, Vitalograph, MIR (Medical International Research), Cohero Health, HGE Health and Respiri. Broad incumbents are Clario and AstraZeneca. Spire Health is listed as an emerging player.
Does TidalSense have an API?
No public API is recorded for TidalSense.